Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2026)

C4 Therapeutics has reported Free Cash Flow over the past 8 years, most recently at -$30.0 million for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 9.92% year-over-year to -$30.0 million; the TTM value through Mar 2026 reached -$96.0 million, down 19.25%, while the annual FY2025 figure was -$99.3 million, 51.98% down from the prior year.
  • Free Cash Flow for Q1 2026 was -$30.0 million at C4 Therapeutics, down from -$22.2 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$5.0 million in Q2 2024 and troughed at -$33.3 million in Q1 2023.
  • A 5-year average of -$24.0 million and a median of -$25.3 million in 2022 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: soared 73.79% in 2024 and later tumbled 147.66% in 2025.
  • Year by year, Free Cash Flow stood at -$28.1 million in 2022, then rose by 20.14% to -$22.5 million in 2023, then grew by 20.23% to -$17.9 million in 2024, then dropped by 23.58% to -$22.2 million in 2025, then plummeted by 35.32% to -$30.0 million in 2026.
  • Business Quant data shows Free Cash Flow for CCCC at -$30.0 million in Q1 2026, -$22.2 million in Q4 2025, and -$31.5 million in Q3 2025.